JP2016517401A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016517401A5 JP2016517401A5 JP2015562243A JP2015562243A JP2016517401A5 JP 2016517401 A5 JP2016517401 A5 JP 2016517401A5 JP 2015562243 A JP2015562243 A JP 2015562243A JP 2015562243 A JP2015562243 A JP 2015562243A JP 2016517401 A5 JP2016517401 A5 JP 2016517401A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antisense oligonucleotide
- composition
- smad7
- colorectal cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims description 54
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 48
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 48
- 101700026522 SMAD7 Proteins 0.000 claims description 42
- 102000049873 Smad7 Human genes 0.000 claims description 42
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 27
- 206010009944 Colon cancer Diseases 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000002702 enteric coating Substances 0.000 claims description 3
- 238000009505 enteric coating Methods 0.000 claims description 3
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 28
- 229920001577 copolymer Polymers 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
- 239000003112 inhibitor Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361790488P | 2013-03-15 | 2013-03-15 | |
| US61/790,488 | 2013-03-15 | ||
| US201361847287P | 2013-07-17 | 2013-07-17 | |
| US61/847,287 | 2013-07-17 | ||
| PCT/EP2014/055195 WO2014140333A1 (en) | 2013-03-15 | 2014-03-14 | Methods of treating colorectal cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018199148A Division JP2019026649A (ja) | 2013-03-15 | 2018-10-23 | 結腸直腸癌を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016517401A JP2016517401A (ja) | 2016-06-16 |
| JP2016517401A5 true JP2016517401A5 (OSRAM) | 2017-04-20 |
| JP6502863B2 JP6502863B2 (ja) | 2019-04-17 |
Family
ID=50390057
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562243A Active JP6502863B2 (ja) | 2013-03-15 | 2014-03-14 | 結腸直腸癌を処置する方法 |
| JP2018199148A Withdrawn JP2019026649A (ja) | 2013-03-15 | 2018-10-23 | 結腸直腸癌を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018199148A Withdrawn JP2019026649A (ja) | 2013-03-15 | 2018-10-23 | 結腸直腸癌を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP2970419B8 (OSRAM) |
| JP (2) | JP6502863B2 (OSRAM) |
| KR (1) | KR102232623B1 (OSRAM) |
| CN (1) | CN105008394B (OSRAM) |
| AU (1) | AU2014229985B2 (OSRAM) |
| CA (1) | CA2903597C (OSRAM) |
| ES (1) | ES2673209T3 (OSRAM) |
| MX (1) | MX363746B (OSRAM) |
| NZ (1) | NZ711564A (OSRAM) |
| RU (1) | RU2674147C2 (OSRAM) |
| WO (1) | WO2014140333A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| RS56049B1 (sr) | 2008-11-13 | 2017-09-29 | Nogra Pharma Ltd | Antisens kompozicije i postupci za pripremu i upotrebu istih |
| KR102099990B1 (ko) | 2011-09-15 | 2020-04-13 | 노그라 파마 리미티드 | 항-smad7 요법의 반응성을 모니터링하는 방법 |
| RU2667960C2 (ru) | 2012-04-18 | 2018-09-25 | Ногра Фарма Лимитед | Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| CN106573065A (zh) | 2014-05-09 | 2017-04-19 | 诺格尔制药有限公司 | 用于治疗炎症性肠病的方法 |
| EP3207136A1 (en) | 2014-10-17 | 2017-08-23 | Nogra Pharma Limited | Methods and compositions for treating a subject with a smad7 antisense oligonucleotide |
| JP2018529726A (ja) * | 2015-09-30 | 2018-10-11 | セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー | Ｔｌｒ調節因子及び使用方法 |
| US11162097B2 (en) | 2016-02-23 | 2021-11-02 | Nogra Pharma Limited | Methods of treating intestinal fibrosis using SMAD7 inhibition |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159697A (en) * | 2000-01-19 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad7 expression |
| ITRM20030149A1 (it) * | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| ITRM20030393A1 (it) * | 2003-08-11 | 2005-02-12 | Giuliani Spa | Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb. |
| US7402574B2 (en) * | 2004-03-12 | 2008-07-22 | Avi Biopharma, Inc. | Antisense composition and method for treating cancer |
| US20080114287A1 (en) * | 2006-11-14 | 2008-05-15 | Kar Neng Lai | Ultrasound Microbubble Mediated Genes Delivery System |
| RS56049B1 (sr) * | 2008-11-13 | 2017-09-29 | Nogra Pharma Ltd | Antisens kompozicije i postupci za pripremu i upotrebu istih |
| UA107562C2 (uk) * | 2008-12-05 | 2015-01-26 | Спосіб лікування псоріазу | |
| KR102099990B1 (ko) * | 2011-09-15 | 2020-04-13 | 노그라 파마 리미티드 | 항-smad7 요법의 반응성을 모니터링하는 방법 |
-
2014
- 2014-03-14 CN CN201480016188.7A patent/CN105008394B/zh active Active
- 2014-03-14 WO PCT/EP2014/055195 patent/WO2014140333A1/en not_active Ceased
- 2014-03-14 CA CA2903597A patent/CA2903597C/en active Active
- 2014-03-14 JP JP2015562243A patent/JP6502863B2/ja active Active
- 2014-03-14 EP EP14713401.9A patent/EP2970419B8/en active Active
- 2014-03-14 KR KR1020157029231A patent/KR102232623B1/ko active Active
- 2014-03-14 MX MX2015013255A patent/MX363746B/es active IP Right Grant
- 2014-03-14 AU AU2014229985A patent/AU2014229985B2/en active Active
- 2014-03-14 ES ES14713401.9T patent/ES2673209T3/es active Active
- 2014-03-14 RU RU2015140572A patent/RU2674147C2/ru active
- 2014-03-14 NZ NZ711564A patent/NZ711564A/en unknown
-
2018
- 2018-10-23 JP JP2018199148A patent/JP2019026649A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016517401A5 (OSRAM) | ||
| JP2017529382A5 (OSRAM) | ||
| RU2015140572A (ru) | Способы лечения колоректального рака | |
| JP2014515373A5 (OSRAM) | ||
| JP2016540738A5 (OSRAM) | ||
| JP2010535508A5 (OSRAM) | ||
| FI3166615T3 (fi) | Kelatoituja fosforotioaattinukleiinihappopolymeerejä käytettäväksi yhdistelmänä HBV-polymeraasin inhibiittorin kanssa hepatiitti B- ja hepatiitti D -virusinfektioiden hoitamiseksi | |
| IL263110B (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
| WO2009026292A1 (en) | Dosing methods for treating disease | |
| FI3897672T3 (fi) | HBV-yhdistelmähoito | |
| JP2015504438A5 (OSRAM) | ||
| JP2016516773A5 (OSRAM) | ||
| RU2016137289A (ru) | Схема применения соединения fgf-18 | |
| JP2011515357A5 (OSRAM) | ||
| CN102438608A (zh) | 包含ave8062和索拉非尼的抗肿瘤组合 | |
| JP2024170590A (ja) | タウロリジン加水分解産物による神経芽細胞腫治療 | |
| WO2016081773A2 (en) | Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides | |
| EP1812036A2 (en) | Histone deacetylase inhibitors and methods of use | |
| JP2014148552A5 (OSRAM) | ||
| FI3352735T3 (fi) | Pitkitetysti vapauttavia olantsapiiniformulaatioita | |
| MY165964A (en) | Preventive or therapeutic agent for fibrosis | |
| MX2022012923A (es) | Inhibidores de trpc6 para tratar afecciones respiratorias. | |
| WO2011031890A4 (en) | Cancer stem cell-targeted and drug resistant cancer therapy | |
| JP2012518602A5 (ja) | 癌の予防または処置に使用されるインヒビター及び方法 | |
| ES2703739T3 (es) | Combinación terapéutica que comprende un inhibidor aurora cinasa y un agente antineoplásico |